

Dmitri B Kirpotin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3222014/publications.pdf>

Version: 2024-02-01

57
papers

7,338
citations

76326

40
h-index

155660

55
g-index

58
all docs

58
docs citations

58
times ranked

8080
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics. <i>MAbs</i> , 2022, 14, .	5.2	2
2	Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic. <i>Pharmaceutics</i> , 2020, 12, 996.	4.5	6
3	Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs. <i>Journal of Controlled Release</i> , 2019, 310, 47-57.	9.9	27
4	Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. <i>Nature Biomedical Engineering</i> , 2019, 3, 264-280.	22.5	40
5	Companion Diagnostic ⁶⁴ Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines. <i>Theranostics</i> , 2018, 8, 2300-2312.	10.0	47
6	⁶⁴ Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4190-4202.	7.0	280
7	Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. <i>MAbs</i> , 2017, 9, 58-67.	5.2	23
8	Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle. <i>MAbs</i> , 2015, 7, 42-52.	5.2	21
9	A gradient-loadable ⁶⁴ Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 155-165.	3.3	51
10	Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. <i>Nanomedicine</i> , 2014, 9, 2099-2108.	3.3	19
11	Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. <i>Nanomedicine</i> , 2013, 8, 1913-1925.	3.3	22
12	Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. <i>Neuro-Oncology</i> , 2013, 15, 189-197.	1.2	69
13	Building and Characterizing Antibody-Targeted Lipidic Nanotherapeutics. <i>Methods in Enzymology</i> , 2012, 502, 139-166.	1.0	21
14	Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. <i>Neuro-Oncology</i> , 2011, 13, 1288-1295.	1.2	22
15	Development of a highly stable and targetable nanoliposomal formulation of topotecan. <i>Journal of Controlled Release</i> , 2010, 141, 13-21.	9.9	103
16	Canine spontaneous glioma: A translational model system for convection-enhanced delivery. <i>Neuro-Oncology</i> , 2010, 12, 928-940.	1.2	93
17	Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 741-751.	2.3	65
18	Improved Pharmacokinetics and Efficacy of a Highly Stable Nanoliposomal Vinorelbine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 328, 321-330.	2.5	45

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. Journal of Pharmaceutical Sciences, 2008, 97, 4696-4740.	3.3	237
20	Targeted Tumor Cell Internalization and Imaging of Multifunctional Quantum Dot-Conjugated Immunoliposomes in Vitro and in Vivo. Nano Letters, 2008, 8, 2851-2857.	9.1	256
21	Preclinical Manufacture of Anti-HER2 Liposome-Inserting, scFv-PEG-Lipid Conjugate. 2. Conjugate Micelle Identity, Purity, Stability, and Potency Analysis. Biotechnology Progress, 2008, 21, 221-232.	2.6	74
22	Preclinical Manufacture of an Anti-HER2 scFv-PEG-DSPE, Liposome-Inserting Conjugate. 1. Gram-Scale Production and Purification. Biotechnology Progress, 2008, 21, 205-220.	2.6	79
23	Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Molecular Cancer Therapeutics, 2008, 7, 569-578.	4.1	47
24	Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging. Journal of Neurosurgery, 2008, 108, 989-998.	1.6	85
25	Impact of Single-chain Fv Antibody Fragment Affinity on Nanoparticle Targeting of Epidermal Growth Factor Receptor-expressing Tumor Cells. Journal of Molecular Biology, 2007, 371, 934-947.	4.2	164
26	Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Molecular Immunology, 2007, 44, 3777-3788.	2.2	44
27	Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro-Oncology, 2007, 9, 393-403.	1.2	102
28	Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Molecular Cancer Therapeutics, 2007, 6, 2737-2746.	4.1	76
29	Development of a Highly Active Nanoliposomal Irinotecan Using a Novel Intraliposomal Stabilization Strategy. Cancer Research, 2006, 66, 3271-3277.	0.9	305
30	Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models. Cancer Research, 2006, 66, 6732-6740.	0.9	1,009
31	Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model1. Neuro-Oncology, 2006, 8, 205-214.	1.2	91
32	Convection-enhanced delivery of liposomal doxorubicin in intracranial brain tumor xenografts. Targeted Oncology, 2006, 1, 79-85.	3.6	10
33	A novel assay for monitoring internalization of nanocarrier coupled antibodies. BMC Immunology, 2006, 7, 24.	2.2	29
34	Novel Nanoliposomal CPT-11 Infused by Convection-Enhanced Delivery in Intracranial Tumors: Pharmacology and Efficacy. Cancer Research, 2006, 66, 2801-2806.	0.9	149
35	Intraliposomal Trapping Agents for Improving In Vivo Liposomal Drug Formulation Stability. , 2006, , 149-168.		0
36	Epidermal Growth Factor Receptor-Targeted Immunoliposomes Significantly Enhance the Efficacy of Multiple Anticancer Drugs <i>in vivo</i> . Cancer Research, 2005, 65, 11631-11638.	0.9	365

#	ARTICLE	IF	CITATIONS
37	Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes. <i>Clinical Cancer Research</i> , 2005, 11, 3392-3401.	7.0	55
38	CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS. <i>Annual Review of Pharmacology and Toxicology</i> , 2005, 45, 495-528.	9.4	554
39	Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer Cells. <i>Cancer Research</i> , 2004, 64, 704-710.	0.9	90
40	Extensive Distribution of Liposomes in Rodent Brains and Brain Tumors Following Convection-Enhanced Delivery. <i>Journal of Neuro-Oncology</i> , 2004, 68, 1-9.	2.9	128
41	Distribution of Liposomes into Brain and Rat Brain Tumor Models by Convection-Enhanced Delivery Monitored with Magnetic Resonance Imaging. <i>Cancer Research</i> , 2004, 64, 2572-2579.	0.9	217
42	Development of ligand-targeted liposomes for cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2004, 8, 335-353.	3.4	147
43	Liposome-based approaches to overcome anticancer drug resistance. <i>Drug Resistance Updates</i> , 2003, 6, 271-279.	14.4	151
44	Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. <i>Cancer Research</i> , 2003, 63, 3154-61.	0.9	218
45	Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2002, 1591, 109-118.	4.1	156
46	Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. <i>Clinical Cancer Research</i> , 2002, 8, 1172-81.	7.0	163
47	Biological Effects of Anti-ErbB2 Single Chain Antibodies Selected for Internalizing Function. <i>Biochemical and Biophysical Research Communications</i> , 2001, 280, 274-279.	2.1	51
48	Cationic Liposomes Coated with Polyethylene Glycol As Carriers for Oligonucleotides. <i>Journal of Biological Chemistry</i> , 1998, 273, 15621-15627.	3.4	183
49	Targeting of Drugs to Solid Tumors Using Anti-Her2 Immunoliposomes. <i>Journal of Liposome Research</i> , 1998, 8, 425-442.	3.3	19
50	Targeting of sterically stabilized liposomes to cancers overexpressing HER2/neu proto-oncogene. , 1998, , 325-345.		3
51	Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes. <i>Journal of Liposome Research</i> , 1997, 7, 391-417.	3.3	28
52	Immunoliposomes for Cancer Treatment. <i>Advances in Pharmacology</i> , 1997, 40, 399-435.	2.0	90
53	Sterically Stabilized Anti-HER2 Immunoliposomes: Design and Targeting to Human Breast Cancer Cells in Vitro. <i>Biochemistry</i> , 1997, 36, 66-75.	2.5	412
54	Anti-HER2 immunoliposomes for targeted therapy of human tumors. <i>Cancer Letters</i> , 1997, 118, 153-160.	7.2	114

#	ARTICLE	IF	CITATIONS
55	Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene) Tj ETQq1 1 0.784314 rgBT14	1.4	10
56	Magnetic targeting of a therapeutic antibody using magnetotropic microspheres of the interpolyelectrolyte coacervation complex. Journal of Magnetism and Magnetic Materials, 1993, 122, 354-359.	2.3	10
57	Synthesis and evaluation of colloidal magnetic iron oxides for the site-specific radiofrequency-induced hyperthermia of cancer. Journal of Magnetism and Magnetic Materials, 1993, 122, 374-378.	2.3	287